



Cite this: *Mol. Syst. Des. Eng.*, 2024, 9, 541

Received 30th January 2024,
Accepted 19th March 2024

DOI: 10.1039/d4me00021h

rsc.li/molecular-engineering

Engineering the interaction of short antimicrobial peptides with bacterial barriers

Costanza Montis, ^{ab} Elisa Marelli, ^c Francesco Valle, ^{bd}
Francesca Baldelli Bombelli ^c and Claudia Pigliacelli ^{*c}

While the rise of superbugs and new resistance mechanisms continues decreasing the effectiveness of classical antibiotics, antimicrobial peptides (AMPs) are emerging as a new class of antimicrobials. Still, several drawbacks limit their transition to the clinic, including high production cost, haemolytic activity and possible inactivation by proteases. Here, we give an overview of the most recent work on short AMPs, which are currently a minority in the AMP databases, and of the main AMP design rules, describing their application for short sequences. We also summarize the techniques that can serve to investigate the key steps of the antimicrobial action and that can aid in the engineering of a tuned AMP interaction with bacterial barriers. Particular emphasis is given to the relationship between peptide sequence features and interfacial behaviour, highlighting the role of AMPs self-assembly in the interaction with membranes and their antimicrobial activity.

Design, System, Application

Antimicrobial peptides (AMPs) are expected to be key players in the fight against bacterial infections. Their amino acid and chemical composition clearly determine the physicochemical properties of AMPs in terms of charge, amphipathicity, hydrophobicity, flexibility and non-covalent interaction capacity, features that define their mode of action and selectivity toward microbial cells. The growing knowledge on bacterial membrane structures and susceptibility to AMPs has led to establishment of some recognized design rules, which aid in the development of novel AMPs. Here, we give an overview of well-established design rules and highlight the structure–activity relationship for short AMP design. Particular insight is given into AMP interfacial behaviour and its role in the engineering of a tuned interaction with bacterial barriers and antimicrobial activity.

Introduction

As antimicrobial resistance (AMR) rages, flanked by the exhausted pipeline of new antibiotics, the search for alternative therapeutic options for the treatment of bacterial infections is ever more topical.^{1–4} The era of antibiotics is, indeed, coming to its end, fuelled by the rise of “superbugs” and the continuous global spread of new resistance mechanisms that are making available antibiotics increasingly ineffective.^{5,6} In this scenario, antimicrobial peptides (AMPs) are emerging as a new class of antimicrobials, as shown by the thousands of entries in the AMP databases.^{7,8}



Costanza Montis

Costanza Montis is an Associate Professor of Physical Chemistry at the Department of Chemistry, University of Florence, and a member of the Italian Consortium for Colloid and Surface Science (CSGI). Her main research activity focuses on the understanding of complex phenomena occurring at interfaces, from a physicochemical perspective. Her scientific interests are in Physical Chemistry of Soft Matter and include the biophysical understanding of nano–bio

interfaces, the design of lipid–nanoparticle hybrid materials for biomedical applications, and the engineering/characterisation of biogenic extracellular vesicles. Her current research is focused on the development of advanced lipid formulations for delivery of actives, RNA technologies and cosmetic applications, and on the design and development of complex biomimetic systems via microfluidics.


^a Department of Chemistry and CSGI, University of Florence, Florence, Italy

^b Consorzio Interuniversitario per lo Sviluppo dei Sistemi a Grande Interfase, 50019 Firenze, Italy

^c Laboratory of Supramolecular and Bio-Nanomaterials (SupraBioNano Lab), Department of Chemistry, Materials, and Chemical Engineering “Giulio Natta”, Politecnico di Milano, Via Luigi Mancinelli 7, 20131 Milan, Italy.

E-mail: claudia.pigliacelli@polimi.it

^d Consiglio Nazionale delle Ricerche, Istituto per lo Studio dei Materiali Nanostrutturati, 40129 Bologna, Italy



Mini review

Peptides are used as natural defensive molecules in all domains of life, and according to their primary sequence and secondary structure, they exert antimicrobial activity through multiple mechanisms, as summarized in Fig. 1.⁹ Among them, disruption of the bacterial membrane is the most reported one, followed by the triggering of bacterial DNA damage upon membrane translocation. Achieving fine control over AMP interfacial behaviour is key.¹⁰ Indeed, for both membrane disrupting and translocating peptides, their interaction with the bacterial membrane and wall represents

a first and crucial step.^{11,12} Generally, two main physical features need to be tuned to properly engineer this interaction: cationic charge content, that promotes selectivity for negatively charged microbial cytoplasmic membranes over zwitterionic eukaryotic ones, and a significant proportion of hydrophobic residues that facilitate interactions with the fatty acyl chains in the lipid bilayer.^{13–15}

Despite the definition of design rules and the high number of AMPs discovered to date, their translation into the clinic is still slow, and several limitations hamper their



Elisa Marelli

Elisa Marelli is a PhD student in Chemical Engineering and Industrial Chemistry at Politecnico di Milano. She graduated in Materials Engineering and Nanotechnology at the same university with a thesis on biocomposites based on fibrillated nanocellulose and amyloidogenic peptides. Her current research activity is focused on investigating the self-assembly mechanisms of short amino acid sequences and exploring their potential in designing novel hybrid biomaterials for diverse applications, from biomedicine to nanotechnology.



Francesco Valle

Francesco Valle is a Senior Researcher at the Institute for the Study of Nanostructured Materials of Consiglio Nazionale delle Ricerche. He received his Master's degree in Physics from the University of Roma "La Sapienza" in 1999, and his PhD in Science from the University of Lausanne, Switzerland. He was a Post-doctoral Fellow at the Ecole Polytechnique Federale de Lausanne (EPFL) and at the University of Bologna. He joined CNR-ISMN Bologna in 2009 as a Research Scientist. His research interests include nanomechanics, polymer physics, single-molecule techniques, protein folding and extracellular vesicles.



Francesca Baldelli Bombelli

Francesca Baldelli Bombelli is an Associate Professor of Chemistry at Politecnico di Milano. She was a Group Leader at the European Centre of Nanomedicine (CEN – <https://nanomedicen.eu/>) in 2013–2015 and a Lecturer in Nanotechnology and Colloid Science at the School of Pharmacy, UEA, Norwich, UK in 2011–2014. Her research interests are focused on the development of engineered nanomaterials (ENMs) for the diagnosis and treatment of untreatable diseases such as cancer and neurodegenerative pathologies. She has recently developed fluorinated nanomaterials (FNMs) with exceptional multiscale F-MRI and Raman microscopy imaging properties. She is also interested in studying the effect of fluorination on the promotion of cytosolic delivery of biomolecules and nanoparticles. Moreover, her research also aims at investigating the interactions between ENMs and cellular machinery to improve their in vivo efficiency and evaluate possible toxicity effects.



Claudia Pigliacelli

Claudia Pigliacelli is a Tenure-Track Assistant Professor of Chemistry at the Department of Chemistry, Materials, and Chemical Engineering "Giulio Natta" of Politecnico di Milano. She received her PhD in Pharmacy from the University of East Anglia (UK) in 2015. She was a research assistant and postdoc researcher at Politecnico di Milano (2013–2016), and worked as a postdoc at Aalto University (Finland, 2016–2019) and at the Centro de Investigaciones Científicas Avanzadas (CICA, Universidade da Coruña, Spain, 2020). Her research interests focus on the design of nanoscale systems based on biomolecules (peptides and proteins) and inorganic nanoparticles, whose applications are not limited to but mainly fall within the biomedical field.






Fig. 1 Summary of AMP intracellular and extracellular modes of action.

confirmation as new therapeutics.^{8,16–18} Among them, high cost of production, when compared to classical antibiotics, and susceptibility to proteases represent critical issues. The cost-effectiveness of AMPs could potentially be improved by decreasing the length of the polypeptide sequences. Also, the presence of a good proline (Pro, P) or tryptophan (Trp, W) content, the chemical modification of peptides aimed at increasing hydrophobicity,¹⁹ and the use of D-amino acids have shown to strongly improve AMP resistance to proteolysis. But translating the key features that have been identified as essential to control AMP behaviour in a shorter sequence can be challenging, and such a difficulty is reflected in the low number of AMPs shorter than 10 amino acids (AAs) that can be found in the database.

In this minireview, we aim to give an overview of the most recent work describing short AMPs. We will first introduce the bacterial wall and membrane structures and the AMP-membrane interaction mechanisms reported to date, and the techniques that can serve to investigate this key step of the antimicrobial action. Particular emphasis is given to the relationship between sequence features and interfacial behaviour, highlighting the role of AMPs self-assembly in the interaction with bacterial barriers and their antimicrobial activity.

Bacterial membranes and walls: disruption and translocation

The integrity and selective permeability of the lipid bilayer membrane are essential features for cell viability and functionality of every living organism. Membrane permeabilizing and/or disruptive biomolecules play a critical role in both defensive and offensive strategies of living systems and many of

them, such as defensins, amphipathic peptides used as defensive molecules by eukaryotes and plants, and melittin, the main component of the bee venom, have been extensively studied as possible antimicrobial drugs.^{20–22} Defensins and melittin are examples of membrane-disruptive and permeating peptides, respectively, and the study of these and other naturally-occurring peptides has paved the way towards the understanding of AMP interaction with bacterial membranes and the possible mechanism of action both in Gram+ (GP) and Gram- (GN) species.

The cell structure and membrane composition vary significantly between GP and GN bacteria.²³ GP species are surrounded by a cell wall composed of a peptidoglycan (PG) layer with a thickness of tens of nanometres. PG is a single macromolecule made of glycan chains crosslinked by peptide side branches, and by enclosing the bacterial cell, it acts as a constraint that provides mechanical strength to the bacteria.²⁴ Given its porous structure, PG can easily be crossed by many drugs and chemicals. Thus, the main barrier to external agents or molecules is represented by the lipid bilayer membrane (Fig. 2).




Fig. 2 Schematic representation of Gram+ and Gram- bacterial walls and membranes.



Differently, the GN bacteria cell wall comprises an outer membrane (OM), a thin PG layer and an inner membrane (IN). Notably, like other biological membranes, the OM is a lipid bilayer, but it is composed of glycolipids, mostly lipopolysaccharides (LPSs), and phospholipids (PLs) are confined in the inner leaflet of the membrane (Fig. 2).²⁵ Together with contributing to the stiffness and strength of the bacterial cell,²⁶ the OM acts as an efficient barrier, with highly selective porins controlling the uptake of external molecules.²⁷ Importantly, prokaryotic membranes bear negatively charged lipids namely phosphatidylglycerol, cardiolipin and phosphatidylserine and have, therefore, a net negative charge.²⁸

AMP interaction with the bacterial membrane has widely been studied, with the OM being frequently overlooked as a first obstacle for peptides to exert their antimicrobial activity.²⁹ Many AMPs kill bacteria by inducing membrane disruption and leakage of bacterial content, and several models describing the possible mechanism behind this action have been proposed, to date, and already extensively reviewed.^{30,31} Still, the understanding of the interaction mechanisms remains poor for many AMPs, for which an unambiguous mechanistic insight is lacking. Fig. 3 summarizes the models proposed to date, with the barrel-stave (a), carpet (b), and toroidal pore (c) models being the most frequently used to describe the origin of the membrane-lytic action.

Not all antimicrobial peptides exert their major action on membranes. Indeed, an increasing number of peptides have been proved to act on intracellular targets in bacteria. Successful membrane translocation of an AMP strictly depends on its ability to interact with the bacterial membrane and create a passage across the lipid bilayer hydrocarbon core, without causing irreversible membrane damage. This process can happen through different pathways. In detail, the peptide can enter either *via* autonomous membrane translocation and/or through a specific transporter mechanism. In the first case, transient membrane permeabilization occurs. The mechanism behind this process is still under debate, but the leading hypothesis is that, upon their addition, AMPs accumulate on the outer monolayer of the targeted membrane, causing an imbalance of mass, charge, surface tension and lateral pressure. This is followed by a stochastic local dissipation event that relieves the asymmetry caused by peptides, rendering the membrane transiently permeable with a rapid burst of cell content leakage accompanying the peptide translocation. The leakage event is fast and membrane re-sealing takes place in a time frame that allows the bacterial cell survival.^{21,32}

Among specific membrane carriers, ABC transporters SbmA and BacA, belonging to the peptide uptake permease family, are the most known ones.³³ Although essential for bacterial survival and host colonization, these transporters serve well as an aid for AMP membrane translocation,³⁴ particularly for Pro-rich ones.³⁵




Fig. 3 Proposed models for the AMP-bacterial membrane disruption mechanism. a) Barrel-stave model: after AMP insertion into the membrane, a transmembrane pore is formed with the peptides lining the pore lumen in a parallel direction relative to the phospholipid chains, which remain perpendicular to the bilayer plane. b) Toroidal pore model: peptide insertion induces a local membrane curvature in such a way that the pore lumen is lined partly by peptides and partly by phospholipid head groups. c) Carpet model: AMPs interact with the membrane surface and disrupt its integrity by covering it like a carpet. This model does not involve the formation of transmembrane pores; instead, above a minimum AMP concentration, it leads to a detergent-like effect (d) causing membrane breakdown and fragmentation.



Given the multiple possible modes of action of AMPs, tailored design of their primary sequence and secondary structure is essential for engineering a specific antimicrobial mechanism. In the next paragraph, the main design rules established, to date, will be summarized.

Interaction with bacterial membranes – design rules

The amino acid composition clearly determines the physicochemical properties of peptides in terms of charge, amphipathicity, hydrophobicity, flexibility and non-covalent interaction capacity, features that define their mode of action and selectivity toward microbial cells. The growing knowledge on bacterial membrane structures and susceptibility to AMPs has led to establishment of some well-recognized design rules, which aid in the development of novel AMPs. Here, we will give an overview of well-established design rules and highlight the structure–activity relationship for AMP design, including the key points that are still not fully elucidated.

Charge

Given the net negative charge of the bacterial membrane, AMPs are generally cationic, a feature that facilitates their adsorption on bacterial cells. Negatively charged AMPs have also been discovered, but they represent a minority.^{36,37} The peptides' positive charge is directly related to their arginine (Arg; R) and lysine (Lys; K) content, as these cationic AAs mediate the formation of strong electrostatic interactions with anionic lipids of GN and GP bacteria. Notably, both Arg and Lys bear one single positive charge, but with respect to Arg, Lys lacks a guanidinium group, resulting in lower toxicity to eukaryotic cells.³⁸ Several studies have been performed to better understand the impact of charge content on peptides' antimicrobial activity and obtain quantitative information about the minimum charge content needed for an effective bactericidal action.³⁹ In general, an increase in positive charge content leads to a boost in the antimicrobial activity, but increases, at the same time, the AMP haemolytic action, which represents one of the main limitations in AMP confirmation.⁴⁰

In a recent study by López Cascales *et al.*, the antimicrobial activity of two short AMPs, RQWRRWWQR-NH₂ (P4) and RKFRKFKK-NH₂ (P7) with charges +4 and +7, respectively, was compared. The Edmundson wheels obtained for these two peptides (Fig. 4a) clearly showed the presence of two perfectly differentiated portions of similar size, a cationic face (marked with blue cut lines) and a more hydrophobic face (represented by solid yellow lines), for P4, while P7 was characterized by a large cationic portion covering most of the peptide surface and a small hydrophobic moiety. Notably, only P4 showed antimicrobial activity. Thermodynamic studies about peptide insertion in simulated bacterial membranes were performed and revealed

that P7 is unable to reach the threshold concentration necessary to induce membrane disruption. This effect was associated with the poor insertion of the peptide into the lipid bilayer, which is essential to screen out the electrostatic repulsion between neighbouring peptides and favour their subsequent adsorption on the membrane. Differently, P4, owing to its wider hydrophobic portion, could protrude into the lipid bilayer, limiting the electrostatic repulsion between neighbouring peptides. This interfacial behaviour allowed P4 to reach the threshold concentration needed to induce membrane disruption.⁴¹ More recently, a study by Wu *et al.* investigated the impact of the Lys content on the activity of short Fmoc-cationic AMPs. Among three designed peptides, Fmoc-KF, Fmoc-KKF and Fmoc-KKKF, Fmoc-KKF showed the strongest antimicrobial activity against both GP bacteria and GN bacteria, as well as low haemolytic activity. Thus, this work proved that systematically increasing the number of Lys residues in short Fmoc-F AMPs could not improve the antibacterial activity, highlighting the need to properly engineer a combined effect of cationicity, hydrophobicity, and secondary conformation.⁴²

Importantly, also the position of positively charged residues plays a role in AMP activity, as it affects contact frequency between the peptides and cell membrane. Indeed, positive residues at a peptide's extremity (*i.e.*, N- and C-terminal) are more exposed to the solvent and, thus, encounter the membrane with a higher frequency. In contrast, positive residues located in the middle of the peptide sequence tend to be less exposed to the solvent and bind to the lipid bilayer with a lower frequency.⁴⁴

Hydrophobicity

Insertion of the AMP hydrophobic portion into the bacterial membrane core is an essential step for achieving either membrane rupture or permeabilization. Therefore, hydrophobic content is another crucial parameter to be tuned when engineering AMPs.⁴⁵ Notably, while peptides with carbon chain AAs (leucine (Leu), valine (Val)) are energetically favoured for membrane insertion, membrane interfaces tend to prefer AAs with aromatic rings (tryptophan (Trp), phenylalanine (Phe)). Thus, the position of hydrophobic residues is an additional determinant for AMP interaction with membranes, with sequences bearing aromatic residues at the extremity of the peptide sequence having a higher tendency to be adsorbed.⁴⁶

As for the charge content, the AMP hydrophobicity needs to be properly balanced.⁴⁷ Indeed, while its increase usually tends to boost antimicrobial activity, favouring membrane insertion, it can, at the same time, result in a decreased selectivity for bacterial cells, often leading to haemolysis.⁴⁸ Yang *et al.* reported on the antimicrobial activity of a set of nonapeptides designed based on the sequence RXXRXRXL-NH by introducing different ratios (W:I = 1:3, 2:2, and 3:1) of aromatic residues (Trp, W) and branched-chain residues (Ile, I) in the X position.⁴⁹ They found that the presence of






Fig. 4 a) Edmundson representation obtained for P4 (RQWRRWWQR-NH₂) and P7 (RKFRRKFKK-NH₂). b) Molecular dynamics (MD) simulation of the starting configuration of phospholipid bilayers of dipalmitoylphosphatidylcholine (DPPC) in the presence of P4 (yellow) and P7 (red). Blue beads correspond to chloride ions used to balance the total charge existing in the system. Water has been removed for clarity. Panels a and b are reproduced with permission from ref. 41. Copyright © 2018 American Chemical Society. c) Harris-Clark diagram showing the inhibitory activities of peptide sequences against *P. aeruginosa*. Each peptide can be identified by reading the sequence from the N-terminal residue in each ring towards the C-terminal residue at the center of the chart; inhibitory activity (IC₅₀) is indicated for each peptide by the colour of shading in the outermost compartment (i.e. the compartment identifying the N-terminal of each peptide). Grey sections represent peptides which did not exhibit an IC₅₀ within the range of concentrations assayed (0.8–400 μM). d) Effect of peptide length on harmonic means and standard deviations for IC₅₀ and EC₅₀. e) Appearance of *P. aeruginosa* bacteria treated with the peptide RWWRRWR at concentrations of 80 and 400 μM, visualized by SEM (left: scale bars shown are 1 μm in length) and AFM (right: scale bars shown are 2 μm in length). A control image of bacteria not treated with peptide is also shown in both cases. Panels c–e are adapted and reproduced with permission under a Creative Commons License (CC-BY 4.0) from ref. 43. Copyright © 2021 Springer Nature.


Trp at the 4th and 6th *loci* of the nonapeptide sequence facilitated the formation of a β -pleated sheet with a certain turn conformation, indicating that these two positions determine structural flexibility (Fig. 4a and b). The nonapeptides (3IW, W2IW, and IW2I) with the β -pleated sheet conformation showed optimal antimicrobial activity, suggesting a correlation between antimicrobial activity and structural conformation.

In general, amphiphilicity has been found to be far more important for interfacial binding than simple hydrophobicity.⁵⁰ This is confirmed by the work by Clark *et al.*, who recently studied a complete set of all possible peptides, up to 7 residues long, composed of positively charged Arg (R) and/or hydrophobic Trp.⁴³ Peptide sequences comprising only Trp or only Arg were inactive against selected bacteria, highlighting the importance of a mixture of the two residues underpinning activity. Antimicrobial efficacy was typically higher for heptamer peptides containing 3R and 4W, but, importantly, small differences in the sequence could be associated with large differences in activity, with the heptapeptide WWRRRR showing an IC₅₀ value 65-fold higher than WWRRRW. Overall, for penta-, hexa- and

heptapeptides, those with ~60% Trp content exhibited the lowest IC₅₀ concentration against all the tested organisms, but consistently with what was reported by other research groups, a further increase in Trp content, and thus an overall 70–80% hydrophobicity, led to an increased haemolytic activity.^{48,51}

Secondary structure

The formation of an ordered secondary structure upon AMP interaction with phospholipid biomolecules is another key step defining peptide antimicrobial activity. Most AMPs assume an α -helix conformation when in contact with membrane components, but lately β -sheet structures have also been reported for some AMPs. The majority of natural host defence peptides spontaneously assume an α -helix conformation when exerting their antimicrobial activity. Thus, the design of α -helix AMPs has mostly relied, to date, on the identification of common sequence patterns in numerous naturally occurring peptides.⁵² Recently, Lohan *et al.* designed a set of *de novo* short helical peptides with broad-range bactericidal activity and selectivity toward



bacterial cells.⁵³ All peptides showed an irregular spatial structure in aqueous solution. The most effective peptide of the series, $\text{NH}_2\text{-KWLKKWLKWWKK-CONH}_2$, formed an amphipathic helix upon interaction with the lipid bilayer, confirming the correlation of the α -helix content with its membranolytic action.

Teixobactin, an undecapeptide containing five non-canonical AAs discovered for the first time in 2015, represents an innovative AMP effective against several superbugs.⁵⁴ It exerts its antimicrobial action by targeting lipid II, a precursor of peptidoglycan. Teixobactin specifically binds to the pyrophosphate-sugar moiety of lipid II, whereas the N terminus coordinates to the pyrophosphate of another lipid II molecule. Shukla *et al.* recently proved that this configuration favours the formation of a β -sheet for teixobactins bound to the target, creating a supramolecular fibrillar structure, key to antimicrobial action. In detail, small β -sheets are formed upon binding of lipid II (Fig. 5). Then, these assemblies elongate into fibrils that eventually associate into lateral fibrillar sheets, obstructing the biosynthesis of peptidoglycan and causing membrane defects.⁵⁵

Importantly, secondary structure formation is crucial also for cell-penetrating AMPs having an intracellular target.⁵⁴ Most cell-penetrating peptides (CPPs) have a disordered/random coil conformation in solution, but the presence of α -helices and β -sheets when in contact with the bacterial membrane and cells has been reported. In general, it can be

argued that peptides undergoing a greater extent of helicity are more likely to cause large phase perturbations in a membrane and are, therefore, more likely to kill the bacteria through membrane damage. This is consistent with the widely reported tendency of Pro, known as a helix-breaker, in promoting peptide translocation ability. Due to its cyclic structure, the Pro amide group lacks the proton needed to form hydrogen bond (HB) interactions, which are essential for stabilising α -helix and β -sheet structures.⁵⁶ Therefore, Pro usually induces regions of helix distortions with higher flexibility in transmembrane helices.⁵⁷ Typically, the cell penetration efficiency of peptides tends to increase with their amphipathicity content, but when a high value of hydrophobicity is reached, peptides predominantly remain on plasma cell membranes.⁵⁸ Overall it is not possible, from the reported literature, to correlate a specific secondary structure with an efficient passage through the membrane, as the uptake process was obtained with peptides characterized by an α -helical, a β -sheet, or a random coil structure (Table 1).

Non-covalent interaction capacity

AMP interaction with bacterial component membranes is based on an interplay of weak interactions, namely electrostatic interactions, hydrophobic effect and HBs. Besides being crucial for the stabilization of the peptide secondary structure, HBs are a determinant for direct AMP




Fig. 5 a) Chemical structure of teixobactin. b) Mode of action model for teixobactin. Teixobactin first forms small β -sheets upon binding of lipid II, and then elongates into fibrils that eventually associate into lateral fibrillar sheets, obstructing biosynthesis of peptidoglycan and causing membrane defects. c) Snapshots of a timelapse HS-AFM video following the assembly of teixobactin–lipid II fibrils. Images were obtained on a supported lipid bilayer containing 1% (mol) lipid II in the presence of 800 nM teixobactin, added after 24 s. Image acquisition rate of 0.5 frames per second. d) Zoomed in view of an HS-AFM image of a fibrillar sheet on the membrane surface, as marked by a white rectangle in (c) at 624 s. The inset in the lower right corner shows the height profile at the dashed line. e) HS-AFM image of a lipid bilayer deformed by teixobactin–lipid II fibrils below the membrane surface, 50 min after the addition of 800 nM teixobactin. The inset shows the height profile at the dashed line. Panels a–e are reproduced and adapted with permission under a Creative Commons License (CC-BY 4.0) from ref. 55. Copyright © 2022 Springer Nature.




Table 1 Summary of general AMP design rules and their application in short AMP development

Feature	General rule	Short AMPs	Exceptions
Charge	Cationic content favors the interaction with bacterial cells and antimicrobial activity (up to +9). Positive charges mainly from Arg and Lys content	High charge content hinders membrane insertion. Optimal activity between +2 and +4	Neutral AMPs, as Fmoc-F, ⁵⁹ or specific anionic peptides ³⁷
Hydrophobicity	Hydrophobic residues favor AMPs insertion into the lipid bilayer. Aromatic AAs (Trp, Phe) have higher tendency for adsorption	Peptide hydrophobic content should be balanced to prevent haemolysis. Optimal activity with hydrophobic content $\leq 60\%$	Highly hydrophobic ⁵⁹ or hydrophilic AMPs ⁶⁰
Secondary structure	Ordered secondary structure (α -helix, β -sheet) enhances interaction with lipid bilayer. Optimal secondary structure for efficient peptide translocation not well defined	As for longer peptides. Short AMPs may lack clearly defined secondary structures	Some CPPs with random coil structures ⁵⁸
Non-covalent interaction capacity	Electrostatic interactions, hydrogen bonding, π - π interactions crucial for secondary structure stabilization and membrane perturbation	Optimal activity when Arg and Trp residues are combined (Arg $\geq 40\%$ and multiple adjacent Trp). Extended non-covalent interactions can lead to AMPs self-assembly	–

interaction with the bacterial membrane. Indeed, under physiological conditions, basic residues such as Lys and Arg are HB donors, enabling HB formation with the sulfate and carboxylate moieties of the bilayer phospholipid headgroups. Arg, in particular, can bind more favorably to the membrane interface, owing to the multidentate HB mediated by its guanidine side group, leading to multiple interactions that contribute to membrane perturbation and destabilization.⁶¹ The extensive HB capacity of Arg strongly influences its overall contribution to the creation of a negative membrane curvature, which is topologically necessary for pore formation and disruption of the membrane. A recent study by Arora *et al.* evidenced the direct correlation between membrane deformation and relative amounts of Arg, Lys and Leu in the twelve amino acid-long peptide KLLRLRLKLLRR.⁶² Considering the modification in the membrane spontaneous curvature that can be induced by cationic and hydrophobic AAs (negative and positive, respectively), a higher Arg content was combined with fewer Leu residues, given the additional positive contribution induced by the formation of Arg-mediated multidentate HBs with the membrane. When combined with other hydrophobic residues such as Trp, however, Arg-rich peptides have often been associated with a stronger overall activity, as evidenced by the recurring presence of Arg and Trp even in short AMPs.⁴³ In addition to a balanced cationic/hydrophobic content, the high activity of these peptides has been attributed to the complex interaction pattern that is created between Trp, Arg and the cell membrane.⁶³ Trp itself is able to form HBs with the bilayer components due to its aromatic side chain. Moreover, the negatively charged clouds of its π -electron system can mediate the interaction with the Arg guanidium group, enabling the formation of ion-pair- π interactions.⁶⁴ This allows for a deeper insertion of Arg inside the lipid bilayer, being shielded by the Trp residue. Notably, in contrast to Lys, the unique HB capability of Arg is maintained while engaging in cation- π interactions, facilitating its interaction with the






negatively charged lipid bilayer and promoting disruption of the pathogen membrane.⁶⁵

Non-canonical amino acids and chemical modifications

In an attempt to face drawbacks of AMPs limiting their confirmation as new antimicrobials, several chemical strategies have been employed, to date, to tune their chemical-physical properties and optimize their antimicrobial activity (Table 2). These include N- and/or C-terminal modification, incorporation of unnatural AAs, cyclization and use of non-peptide backbones (peptidomimetics).⁶⁶ Among different N-terminal post-modifications (*e.g.*, glycosylation, PEGylation...), lipidation is one of the most explored approaches, as evidenced by the fact that the most successful AMPs under clinical studies are cyclic lipopeptides, such as daptomycin and polymyxins E and B.⁶⁷ Lipidation, *i.e.* the attachment of a fatty acid moiety to N-terminal residues or Lys side chains, increases peptide hydrophobicity, favouring interfacial binding and membrane permeability. This results in an overall improvement in the antimicrobial activity of peptides without altering their essential properties. Starting from the landmark work of Makovitzki *et al.* on ultrashort cationic lipopeptides, several studies focusing on the optimal combination in terms of both peptide length and fatty acid chain length have been reported.⁶⁸ For instance, Narayana *et al.* identified different peptides ranging from four to twelve AAs derived from the KR12 fragment of the human cathelicidin LL-37 and modified the terminal amine with fatty acid chains with varying length (C6–C14).⁶⁹ Results showed that C10-KR8 (KRIWQRIK) is the most cell selective lipopeptide, with strong activity against *S. aureus*, *E. coli*, and *P. aeruginosa* (MIC 1.6–12.5 μM) and poor haemolytic activity ($\text{HC}_{50} > 200 \mu\text{M}$), while longer fatty acid chains ($>\text{C10}$) lead to higher haemolysis. Increased haemolysis induced by lipopeptides in a fatty acid length-dependent manner is generally known, but the specific peptide sequence plays an essential role in determining the optimal acyl length for the overall AMP activity.^{68,70,71} Narayana *et al.* also



Table 2 Summary of chemical modifications employed to tune the antimicrobial activity of short AMPs

Chemical modification	Residues modified/involved	Impact on antimicrobial activity	Serum stability and resistance to proteolytic degradation	Cell selectivity and haemolysis activity	Ref.
Lipidation	 N-terminal or Lys	Enhanced due to increased membrane affinity	Generally improved	Haemolysis increase in a fatty acid length-dependent manner	68–70
N-Glycosylation	 N-terminal, Lys, Asn	Variable effect	Generally improved	Negligible haemolytic activity	67
D-Amino acids	 –	Variable effect dependent on peptide sequence	High stability at physiological conditions. Significantly improved resistance to enzymatic degradation	Variable effect	72, 73
Halogenation	 Phe, Tyr, Trp	Enhanced membrane affinity and disruption, but overall effect dependent on the halogen type and peptide sequence	Generally improved	Variable effect	74–76, 77
Dimerization and cyclization <i>via</i> disulfide bonds	 Cys	Generally improved	Stable peptide structure with improved resistance to proteolytic degradation	Possible haemolysis increase	51, 78

observed that by substituting the L-amino acids with their D-enantiomeric form, C10-KR8 displayed significantly higher stability under physiological conditions and improved resistance to five different proteases.⁶⁹ AA L-to-D conversion is indeed another common strategy used to improve AMP antimicrobial activity, even though a complete substitution may lead to highly stable peptides, with a consequent undesirable increase of cytotoxicity. Thus, only partial D-amino acid substitution of key residues was proven to be sufficient to enhance the half-life of peptides without compromising the AMP pharmacological profile.⁷²

Halogenation is another valuable and novel approach for optimizing physicochemical and functional features of a wide range of bioactive compounds, including AMPs. Several small halogenated biomolecules with antibacterial properties have been found in nature, where halogen atoms are usually incorporated at phenolic and indolic moieties catalyzed by substrate-specific halogenases.⁷⁹ Similar building blocks are generally used in synthetic halogenated AMPs, leading to an increase of the hydrophobic volume of Phe and Trp residues.⁷³ Molchanova *et al.* demonstrated that inactive peptoids can be converted into effective antibacterials by bromination of Phe residues without leading to increased haemolytic activity or *in vitro* cytotoxicity.⁷⁴ Similarly, a study by Jia *et al.* evidenced the improved proteolytic stability of several halogenated derivatives of the honeybee peptide Jelleine-1 (PFKLSLHL-NH₂), with the iodinated analogue displaying an eightfold increase in the antimicrobial activity with respect to the parent peptide.⁷⁵ Notably, AMPs modified with fluorinated sulfono-γ-AA were recently tested in antimicrobial *in vivo* studies, showing excellent efficacy and safety.⁷⁶ While the impact of halogenation on the physicochemical and structural properties of AMPs is evident

(but still, strongly dependent on the halogen type and peptide sequence),^{80–82} the exact mechanisms behind the enhanced antimicrobial activity are still under investigation.⁷⁷

Finally, in terms of increasing AMP stability, intramolecular disulfide bonds are known to improve the conformational rigidity of peptides.⁵¹ Thus, introducing a cysteine (Cys) residue in the sequence can lead to the formation of peptide dimers or cyclic structures *via* disulfide bridges, which direct and stabilize the supramolecular properties of AMPs, which, in turn, contributes to their antimicrobial activity.⁷⁸

The role of peptide self-assembly

Peptides hold unique self-assembly properties, being able to form highly ordered and hierarchical nanoscale structures. With 20 AAs available and the possibility to further functionalize the peptides' primary sequence, a huge toolbox of self-assembling building blocks is accessible and such a versatility has led to a plethora of peptide nanostructures with different sizes, shapes and functionalities.⁸³ Self-assembly is a key step also for the antimicrobial action of many AMPs.^{83–85} Indeed, as previously discussed in this review, upon contact with microbial membranes, AMPs often undergo structural changes, oligomerizing into aggregates that also account considerably for the diversity of the antimicrobial mode of action.⁴³ Moreover, nanoscale systems of several peptides have been recently proposed as effective antimicrobials.^{85–87} Importantly, supramolecular organization of peptides not only enhances their antimicrobial activity, but can also result in the formation of highly dynamic suprastructures, which are often responsive to external stimuli (such as pH, ionic strength, *etc.*) and more stable (resistant to proteolysis) in the biological environment.⁸⁸



In this regard, the scientific community has made many efforts in designing, with the help of *in silico* simulations, biomimetic peptide sequences forming self-assembled nanostructures with enhanced resistance to enzymatic degradation and able to selectively destabilize bacteria cell membranes.⁸³ The self-assembly behaviour of AMPs is driven by the onset of different types of non-covalent interactions, previously described in this review. To control and predict AMP self-assembly, it is pivotal to carefully design and select distinct peptide building blocks. Several self-assembling peptides have been proposed and studied to date: cyclic peptides, peptides functionalized with hydrophobic chains (alkyl and lipid chains) and surfactant-like peptides.³


About three decades ago, Ghadiri *et al.* first reported that cyclic D,L- α -peptides based on alternating L-Trp and D-Leu self-associated in nanotubular β -sheet-like structures, with exposure of the AAs side groups to the environment.^{89,90} It has been shown that these nanotubes, upon interaction with the bacterial membrane, lay parallel to the lipid plane. This supramolecular arrangement afforded superior proteolytic stability, thanks to the ring rigidity, and enhanced antibacterial activity by increasing membrane permeability and destabilizing transmembrane ion potentials.⁵⁴ The majority of self-assembling cyclic peptides are rich in Trp and Arg residues that provide hydrophobic and positively charged moieties, respectively, and that are key factors for antibacterial activity.^{91,92} Substitution with glutamic acid, instead, seems to reduce this activity due to the electrostatic repulsion with the bacterial membrane.⁹³ More recently, Parang *et al.* have deeply investigated, for example, the assembly and antibacterial activities of cyclic R4W4 and W4KR5 showing their selectivity and bactericidal ability against both GP and GN species.^{94–96} Further, in a recent study, Granja's group designed a modular approach for the preparation of cyclic peptides, having a small hydrophobic core and large hydrophilic surface. Such features led to the parallel stacking of the peptides and to the formation of effective antimicrobial nanotubes.⁶⁰ All these studies highlighted the importance of achieving optimal balance between hydrophobicity and cationic charge for enabling the formation of the nanotubes and obtaining a broad-spectrum antimicrobial action.

Another common strategy used for promoting self-assembly of AMPs is their functionalization with hydrophobic moieties, such as alkyl and lipid chains. Such functionalization leads to higher hydrophobicity and stronger tendency to self-assemble minimizing the number of AAs (PA).⁹⁷ Of note, nature-derived lipopeptides, isolated by fungi and bacteria, have shown to have antimicrobial properties against diverse pathogens.⁹⁸ Thus, peptide lipidation, or more generally functionalization with hydrophobic moieties, has been largely used to promote the antibacterial activity of short peptides.⁹⁹ These peptides, composed of a hydrophilic peptide portion linked to a hydrophobic chain, have an amphiphilic nature and usually self-assemble in nanostructures of different shapes (micelles, vesicles or nanofibers) depending on the packing parameter of the

obtained molecular adduct, maintaining or assuming a β -sheet conformation upon membrane interaction.⁹⁷ This strategy has been pioneered by Stupp and coworkers, who have designed many amphiphilic peptides forming supramolecular aggregates for different biomedical applications.^{100,101} Independent of the shape of the final aggregate, alkylation or lipidation of peptide sequences usually ends up in an increased resistance to proteolysis and enhanced activity against the bacterial membranes, thanks to the multivalence provided by the formation of a nanostructure at the bionanointerface. However, as previously mentioned, the length of the lipid chains was found to be correlated to cytotoxicity as increasing hydrophobicity decreases the specificity to bacterial membranes, with the optimal value in the range of C8 and C16.^{102,103} Lipidated tripeptides, containing a minimal cationic sequence (two Lys residues as either L or D) and a C16 alkyl chain, were reported to form positively charged spherical micelles showing good viability and promising antibacterial activity against both GN and GP bacteria *in vitro*.¹⁰⁴ Interestingly, double-sided lipidated peptides were synthesized using shorter chain lengths (C2–C10) showing high antibacterial activity and lower cytotoxicity with respect to analogues with longer single lipid chains.¹⁰⁵ Further, bolaamphiphiles with a generic structure Arg-(Ala)_x-Arg exhibited different self-association properties as a function of the number of Ala residues with correlated antimicrobial activities against both GP and GN species, thus representing a promising class of potential AMPs (Fig. 6a).¹⁰⁶

Another interesting approach for promoting AMP self-assembly is fluorination. In fact, it has been shown that fluorination of gene and protein vectors enhances cellular internalization, endosome escape and plasma stability with respect to alkylated ones (*i.e.* conventional lipids or polymers).^{108,109} In the same way, the functionalization of peptide sequences of different lengths (7–15 AAs) with linear fluoroalkyl chains resulted in the formation of peptide nanoparticles of about 200 nm with increased proteolytic stability and ability to successfully deliver the peptide intracellularly.¹¹⁰ Thus, with a correct design of the peptide sequence, fluoroalkylation could be exploited for promoting the self-assembly of AMPs in more resistant nanostructures, likely facilitating their interaction with the bacteria lipid membrane and thus enhancing their therapeutic effect.

It is also possible to design a pure peptide sequence (*i.e.* only composed of AAs) bearing intrinsic amphiphilic properties. This strategy has led to the development of short peptides with surface activity able to form nanostructures, such as nanotubes, vesicles and micelles, in aqueous solutions.¹¹¹ In this regard, Chou *et al.* have recently reported promising antimicrobial and antibiofilm activities for a panel of peptides containing WWW or WW motifs.¹⁰⁷ One of the sequences, termed K6, containing two central KK motifs and two positively charged WW moieties at the edges, could engage in a network of hydrophobic and π -electron cloud interactions that led to the formation of spherical aggregates of 150–200 nm in size (Fig. 6e and f). Such a self-assembly pattern was correlated with the highest antimicrobial ability






Fig. 6 a) SAXS data and b) cryo-TEM image of 1 wt% amphiphile RA₉R in water. The red line in panel a corresponds to the fitting using the form factor of a long cylindrical shell. c and d) Antimicrobial activity against c) *E. coli* and d) *S. aureus*. Time 0 is ~5 min from when the peptide is added to the solution. Panels a–d are reproduced with permission under a Creative Commons License (CC-BY) from ref. 106. Copyright © 2019 American Chemical Society. e) Peptide K6 chemical structure and conceptual graph of its main self-assembly driving force. f) SEM image of peptide K6 taken at its minimal inhibitory concentration (MIC) for *P. aeruginosa* (4 μM) (insert: average size of peptide K6 nanoparticles). g) Minimal inhibitory concentration (MIC) values of peptides K1–K6 and gentamicin against bacteria. The color code indicates the dilution of a standard stock of the peptide from 1 to 64 μM, which showed complete growth inhibition. h) 10-fold dilutions of *E. coli* OMNIMAX were plated after 30 min of treatment with the respective peptides or in PBS at 37 °C, showing the rapid effect of peptide K6. i and j) Antibiofilm activity of peptide K6 with respect to gentamicin, measured through crystal violet staining. Panels e–j are reproduced with permission under a Creative Commons License (CC-BY-NC-ND 4.0) from ref. 107. Copyright © 2023 PNAS.

of the series (Fig. 6g and h). Even more interestingly, K6 also demonstrated a strong biofilm-disrupting ability against mixed *P. aeruginosa* and *S. aureus* biofilms *in vitro* at low concentrations (Fig. 6i and j). Bacterial biofilms are clusters of bacteria that are attached to a surface and/or to each other and embedded in a self-produced matrix consisting of proteins (e.g., fibrin) and polysaccharides (e.g., alginate), as well as eDNA, and the use of peptides to dismantle such a structure is gaining increasing attention.¹¹² K6 was also successfully tested in a mouse infection model, showing no acute toxicity.

Other examples of amphiphilic peptides were reported by Hamley and co-workers, who have extensively studied the self-assembly behaviour of Ala/Arg peptides, along with their interaction with lipid membranes and their potential use as antimicrobial agents for both GP and GN pathogens.^{101,111,113–115}

Another common category of peptides with surfactant-like behaviour, forming hydrogels with antimicrobial properties is represented by (Fmoc)-protected ultrashort peptides.¹¹⁶ Notably, even Fmoc-Phe, despite not bearing positive charges, exhibits antibacterial activity against GP bacteria.⁵⁹ Moreover, the incorporation of D-AAs in these compounds was beneficial for the resistance to proteolytic degradation.¹¹⁷

Probing AMP interaction with bacterial membranes

A physicochemical approach aimed at establishing clear relationships between the structural and physical features of therapeutics and their functional properties can be instrumental to define the guidelines for a tailored design. Such an approach, which can be of general applicability, is particularly advantageous



in the design of AMPs with their action being strongly dependent on their interfacial behaviour.^{21,118} In this framework, an emerging research topic related to AMPs is the investigation of their interaction with synthetic proxies of bacterial membranes. Compared to the direct *in vitro* investigation of bacteria challenged by AMPs, the employment of bacterial membrane biomimetic systems, made of either synthetic lipids or bacterial membrane extracts, has multiple advantages.¹¹⁹ First, the membrane composition of the artificial proxies can be controlled and finely tuned to investigate and determine the role of selected components in the interaction with AMPs. Furthermore, the geometry and structural arrangement of the biomimetic membrane can be varied at will, to match the requirement of different experimental techniques. Fig. 7 reports some examples of biomimetic membranes.¹²⁰ From a compositional standpoint, the two general reference bacterial membrane structures are those of GP and GN bacteria, reported in Fig. 2 and here discussed in a previous section. Accordingly, the composition of displayed biomimetic membranes can be finely modulated in a controlled manner, by adding specific components, such as LPSs, lipid A, and zwitterionic or anionic lipids, in tuned proportions. Further, from a structural standpoint, depending on the specific phenomenon under investigation and on the available experimental technique, diverse biomimetic systems can be employed, from nanometric or micrometric vesicles (large and giant unilamellar vesicles (LUVs and GUVs)) enclosing an aqueous pool, to planar supported (SLBs) or freestanding lipid bilayers or monolayers.¹²¹ As a general consideration, while the effects of AMPs on bacteria can be strongly dependent on the bacterial type/strain and environmental conditions, and can be investigated through limited experimental tools, probing the interaction of AMPs with biomimetic systems of bacterial membranes gives access to a host of fundamental information gained *via* diverse complementary experimental techniques. Membrane adhesion to a bacterial membrane can be quantified *via* quartz crystal microbalance with dissipation monitoring (QCM-D), nuclear magnetic resonance (NMR) spectroscopy and null ellipsometry,¹²² and structurally resolved at the nanoscale through neutron and X-ray reflectivity (NR, XRR) on SLBs or suspended bilayers,¹²³ and through small-angle X-ray and neutron scattering (SAXS, SANS) on LUVs.¹²⁴ For instance, QCM-

D provides information on the amount of adhered AMPs on the membrane, while NR and XRR allow reconstructing the profile of the bilayer along the *z*-axis (*i.e.*, perpendicularly to the membrane), allowing thus the adhesion “mode” of AMPs to the membrane to be determined, with simple surface adhesion or a significant penetration degree inside the outer or the inner leaflet of the bilayer. Membrane disruption effects can be quantified at the molecular-to-nano length scale through spectroscopic or scattering methods on nanometric vesicles, or through NR, XRR, and atomic force microscopy (AFM) on SLBs.¹²⁵

Specifically, both NR and XRR allow estimating the order/thickness decrease of the lipid bilayer upon incubation with AMPs, as well as its overall hydration increase, suggesting the occurrence of membrane perturbation/disruption effects. As a complementary approach, AFM allows visualizing in 2D the membrane disruption effects at the nanoscale. From a design perspective, these techniques allow determining how the balance between the hydrophobicity and cationic charge of AMPs drives their binding to model bacterial membranes and influences localized disruption, and how topological characteristics of self-assembled AMPs impact bacterial membrane integrity and, ultimately, lead to bacterial death.^{126,127} More extensive structural modifications of the target membrane, such as membrane disruption or morphological alterations occurring at a micrometric length scale, can be detected, for instance, through light microscopy-based techniques, such as fluorescence microscopy, laser scanning confocal microscopy (LSCM),¹²⁸ and total internal reflection fluorescence microscopy (TIRF) on GUVs and fluorescently-labeled SLBs.^{129,130} For instance, by employing fluorescently labelled lipid probes marking the biomimetic membrane, it is possible to determine how incubation of the biomimetic membranes with AMPs affects fluorescence distribution homogeneity, which is a clear hallmark of extensive membrane disruption. The interaction mechanism, either of membrane disrupting or of membrane translocating AMPs, can be resolved on LUVs at a molecular lengthscale through time-resolved SAXS and SANS. For instance, in a recent publication, Lund *et al.* have investigated at a molecular level the membrane impact of




Fig. 7 Schematic representation of bacterial biomimetic membrane models employed to study the mechanism of action of AMPs: A) spherical vesicles, B) supported planar bilayers, C) interfacial monolayers, D) vesicles on planar support and E) unsupported planar bilayers. Reprinted (adapted) with permission from ref. 120. Copyright © 2014 American Chemical Society.






Fig. 8 a) Volume probability distributions for the lipid membrane of vesicles with various amounts of natural peptides, showing the insertion of peptides in the membrane, calculated from small angle X-ray scattering curve fitting of biomimetic lipid vesicle/peptide systems in solution. Reprinted with permission from ref. 131. Copyright 2021 Elsevier. b) High throughput microfluidic system to monitor the membrane interaction of AMPs with large unilamellar vesicles (LUVs): double emulsions are formed on a microfluidic device, each containing a particular AMP. The peptide may or may not interact with the co-encapsulated LUVs, disrupting their membranes. As the LUVs are loaded with a self-quenching concentration of fluorescent dye, their disruption causes release and dilution of the dye, generating a fluorescence signal, which can be detected. Reprinted with permission from ref. 132. Copyright 2022 Wiley. c) Interaction of vectorized AMPs with planar biomimetic membranes (supported lipid bilayers, SLBs): silica NPs of different topologies (smooth, virus-like, mesoporous) are co-incubated with a SLB and their combined interaction with SLBs is monitored, highlighting a prominent impact of the vector topology in driving the interaction at the nano-bio interfaces. Reprinted with permission from ref. 133. Copyright 2021 American Chemical Society.

natural AMPs with nanometric lipid vesicles.¹³¹ By combining SAXS and time-resolved SANS experiments, they explored the hypothesis of membrane pore formation as a consequence of AMP incubation with lipid vesicles, studying both the overall structure of AMP insertion in the lipid membrane (Fig. 8a) and the impact of AMPs on the kinetic mechanisms of lipid transport within the lipid membrane. Interestingly, a similar effect of most AMPs was found, suggesting the possibility of finding a unique description for AMP-induced destabilization of bacterial membranes. Besides the well-established experimental techniques and methods, the versatility of artificial bacterial membrane proxies allows designing and setting-up specific experimental tools to investigate AMP-bacterial membrane proxy interactions. For instance, Dittrich and coworkers developed a double emulsion-based system designed with the aid of microfluidics as a high-throughput tool for fast screening of AMP interaction with LUVs of mammalian-like and bacterial-like cell composition (Fig. 8b).¹³²

The difficulties in achieving a thorough understanding and description of AMP interaction with bacterial membranes are further enhanced in the case of vectorized AMPs. Associating AMPs with nanoparticles or nanostructured delivery systems can be a valuable strategy to enhance AMP ability to interact with cells, or to improve AMP pharmacokinetic properties. For these complex nanosystems, fundamental studies with biomimetic membranes are key to decouple the interfacial effects due to AMPs and to the vector itself and to derive some fundamental information to improve the formulation of AMP-nanovector systems. In a recent study, the topology of different silica-based nanovectors (smooth, mesoporous or virus-like) was explored in

terms of capability to enhance LL37 AMP interaction with a target membrane (Fig. 8c).¹³³ Similarly, the ability of a soft lipid nanocarrier having a cubic structure to efficiently deliver AMPs without hampering their membrane adhesion/disruption function was tested on different mammalian and bacterial mimicking membranes, to determine the relative affinity of the system for different cells.¹²⁹

Overall, these examples show how recent efforts of researchers in the field of AMP development are aimed at exploiting the potentialities of bacterial membrane biomimetic systems both to derive specific information on the behaviour of selected AMPs and, at the same time, to build up a core of new general concepts on the interaction of AMPs with bacterial membranes, which could boost the design of novel systems of superior efficacy, and, ultimately, the full translation of synthetic AMPs into medical practice.

The aid of microscopy

Direct visualization by nanoscale microscopy techniques has represented, in the last few years, the natural complement to the reciprocal space analysis tools described in the previous section.

In the characterization of peptide-membrane interaction, atomic force microscopy (AFM) and electron microscopy (EM) have both played a crucial role in different frames. While EM, taking advantage of its high resolution over several magnification ranges, has been precious to elucidate the membrane permeabilization and bacterial damage at the cellular level, AFM has rather served to gain insight into the molecular basis of peptide-membrane interaction.¹³⁴



In the last two decades, AFM has been the most suitable technique for imaging biological molecules at the nanoscale, under conditions close to the native ones. Indeed, while when employing EM techniques biomolecules have to be imaged in a vacuum or under controlled humidity conditions, single proteins have been imaged and manipulated in a fully liquid environment by AFM, thus allowing their conformation to be monitored during their activity.¹³⁵ Moreover, proteins and polypeptides displaying a symmetric three-dimensional quaternary structure, such as membrane proteins, have allowed gaining extremely high resolution.^{136–138} Further, AFM represents an effective tool to visualize many of the membrane-mimicking structures described in the previous section. In particular, this microscopy technique has been widely used to study tethered, polymer-cushioned, standing over pores and supported lipid bilayers (SLBs), allowing the structural and physical-chemical properties of their interface to be probed at the nanoscale such as their stability, phase separation, and their interaction with biomolecules.¹³⁹

In the specific frame of AMPs, direct visualization of the fine structure assumed upon their interaction with membranes has contributed to unveiling the different mechanisms of actions. Several membrane disruption models have been identified by AFM, such as barrel-stave and toroidal pore models, by imaging the pores formed at different length scales, while membrane roughening has been used to support the carpet models.¹⁴⁰ When membrane thinning has been thought to be the mechanism of action, a direct measurement of the bilayer thickness has been performed with extremely high accuracy to decipher the role of peptide-induced changes in membrane interfacial tension.¹⁴¹ In addition, when preparing bilayers with different lipid phases, AFM can reveal differences in peptide preference for binding onto them or, when accessible, on the phase boundaries.¹⁴² Importantly, together with probing the membrane bilayer structure, AFM also allows tracking of the AMP self-assembly. Such an approach has been recently employed by Shen and coworkers to investigate the activity of a new short AMP, KRRFFRRK (termed FF8), designed to target the negatively charged lipid membrane and self-assemble into nanofibers on it.¹⁴³

Besides its main role of imaging, AFM is also widely used to mechanically manipulate biomolecules. In the case of peptide-membrane interaction, this has a twofold implication: (1) measuring the interaction force between the peptide and the phospholipids, and thus correlating such force with the AMP impact on the membrane, and (2) characterizing the bilayer fluidity and mechanical properties. In the first case, the interaction force can be directly measured by bringing into contact a peptide tethered to the AFM probe with a bilayer formed on the substrate surface and then measuring the load necessary to break the formed bond.¹⁴⁴ In the second one, by indenting the membrane with the AFM tip, one can measure the force necessary to punch through the lipid layers, which is related to their cohesive energy, their packing and the overall fluidity.¹⁴⁵ Such a nanomechanical approach has been applied by Manioglou

and coworkers to discover new molecular insights into the mechanism of action of polymyxins, a group of cyclic heptapeptides bearing an N-terminal fatty acid, currently used in the clinic against the superbugs *Acinetobacter baumannii* and *Pseudomonas aureginosa*.¹⁴⁶ In particular, they utilized outer membrane vesicles (OMVs) of Gram-negative *E. coli* to form native membrane patches containing LPSs in the outer leaflet. Their study revealed that, upon exposure to the membrane patches, polymyxins arrange the LPSs into hexagonal assemblies to form crystalline structures. This led to a decreased membrane thickness and an increased membrane area and stiffness, proving that the crystalline hexagonal assembly formation constitutes the mechanism of action of polymyxins (Fig. 9a–c).

It is important to mention that high resolution AFM imaging is not limited to ideal samples, such as synthetic lipid bilayers on flat surfaces, but is still informative when working with the entire living bacteria showing nanoscale changes in their membrane.^{148,149} AMPs alter cell physical properties, specifically morphology, volume, surface roughness, and stiffness. These effects can be fully investigated by AFM working with living cells in their physiological environment and further corroborated by EM techniques, which can be complementary to AFM to fully elucidate the AMP mechanism of action and impact on the bacterial morphology.¹⁵⁰ The role of EM techniques in AMP design and characterization becomes even more relevant when employed under cryogenic conditions that allow samples to be preserved in their frozen-hydrated (native-like) state. More recently, cryo-electron tomography (cryo-ET) has been emerging as an excellent method for studying the three-dimensional (3D) structure of living cells. In this framework, Chen and coworkers reported on the use of cryo-ET and AFM to study how the *de novo*-designed peptide composed of fourteen AAs (Myr-WKKLKKLLKKLKKL-NH₂; Myr: myristoylation), termed pepD2M, interacted with the natural membrane of Gram-negative bacteria.¹⁴⁷ This study pioneered the use of cryo-ET in AMP design. As shown in Fig. 9, tomography reconstruction of cryo-EM images allowed visualizing the severe disruption exerted by pepD2M on the *E. coli* membrane, and imaging and measuring the size of the formed pores. AFM was instead used to prove that pepD2M effectively removes the lipids from the bacterial OM. The combination of the experimental data obtained with the two microscopy approaches allowed the authors to identify the exact mechanism of action of pepD2M, which differed from the one predicted for an amphipathic and α -helix forming peptide which usually forms transmembrane pores. Indeed, the removal of lipids from the OM by pepD2M leads to the formation of irregular pores destabilizing the bacterial wall. This allows pepD2M to reach the IM where the membranolytic action is fully exerted, leading to loss of the cytoplasmic material and shrinkage of the bacterial cell.

Future outlook and conclusions

AMPs are expected to become future key players in the fight against antimicrobial resistance and superbug emergence. This







Fig. 9 a) AFM topographs of an OM patch before and after incubation with polymyxin E. Scale bars, 200 nm (overview) and 20 nm (zoom-in). b) Growth curves of the *E. coli* MG1655 WT (gray) and MG1655MCR-1 (red) strains at different polymyxin concentrations. Above the minimal inhibitory concentration (MIC) of 0.5–1 mg L⁻¹, the growth of the *E. coli* MG1655 WT strain is inhibited. c) Schematic representation of the polymyxin structure, where polymyxin E has D-Leu (L) and polymyxin B has D-Phe (F) in the 6th position and AFM topographs of OM patches from the *E. coli* MG1655 WT strain upon incubation with different polymyxin E and polymyxin B variants (50 mg L⁻¹). Crystalline structures are formed with the enantiomer variant Thr10 (L → D) and with full and intermediate-length polymyxin E variants. Structures are not formed in the polymyxin variant Dab9 (+) → (–) and polymyxin E nonapeptide variant. With polymyxin B variants, crystalline structures are formed in all cases. Panels a–c are reproduced and adapted with permission under a Creative Commons License (CC-BY 4.0) from ref. 146. Copyright © 2022 Springer Nature. d) CD spectra of pepD2M in water and in buffer. Black line: without liposomes; red line: mixed with PE/PG liposomes; green line: mixed with DOPC liposomes. Illustrations of the structural change that occurs upon conditional changes are shown above the spectra. e) Cryo-ET slices of two minicells treated with pepD2M and their inner and outer membranes. IM: cyan; OM: violet; PG: yellow; released material: green. Scale bar = 100 nm. Pores are pointed by arrows with different colors. Two volcanic-crater-like pores are indicated by the red and orange arrows. Panels d and e are reproduced and adapted with permission under a Creative Commons License (CC-BY 4.0) from ref. 147. Copyright © 2023 Springer Nature.

is proved by the intense research effort made by scientists from several scientific communities to better understand the mechanism of action of these peptides and optimize their design towards new effective therapeutic options.

To date, AMPs have mostly been studied as agents able to kill bacteria targeting intracellular components or bacterial walls and membranes. Still, as described in the work by Chou and coworkers previously discussed in this review,¹⁰⁷ additional antimicrobial effects have recently been reported, with AMPs shown to be able to suppress biofilm formation and even induce the dissolution of existing biofilms.^{151,152} A recent example of the role of AMPs as antibiofilm agents was reported by Harding *et al.*, who designed cyclic-ERWGHDFIK, a potent inhibitor of the *P. aeruginosa* aminopeptidase (PaAP), highly abundant in the biofilm matrix where it contributes to its formation and nutrition.¹⁵³ Notably, the

antibiofilm action shown by many AMPs also opens up to their use in the development of biomaterials endowed with intrinsic antimicrobial activity, which could limit the insurgence of infections.^{154,155}

In this review, we have highlighted the main steps of the AMP engineering process and we chose to focus on short AMPs which, we believe, have a more realistic chance to replace classical antibiotics, given their lower cost and faster production, when compared to longer sequences. We summarized the main design rules that can aid in developing effective AMPs by modulating physicochemical determinants and obtain the desired biological parameters.¹⁵⁶ As recently stated by Gagat *et al.*, the engineering of novel AMPs could significantly be eased by a database of non-AMPs, currently not available, reporting on peptide sequences that were found to be inactive for specific bacterial species.¹⁵⁷ Access to such a database would undoubtedly reduce the number



of studies and peptide sequences tested and would provide a precious tool in the identification of effective AMPs and the optimization of their features. Further, given the charged nature of almost all AMPs, we believe that the study of their interaction, not only with bacterial membranes and cells, but also with the host biological fluids, would be functional for the identification of effective peptide sequences. This is currently an underexplored side of AMP research, but probing the bio-nano interaction taking place in the physiological environment would be key, in particular, to nanoscale AMP systems, which could be deeply changed in terms of surface charge, composition and features upon contact with physiological proteins, salts and biosurfactants.¹⁵⁸

Overall, we have provided an overview of the most recent work on short AMPs and on the techniques that are key to studying their chemical and physical features, as well as for the assessment of their interaction with bacterial walls and membranes. Bearing in mind the multiple opportunities offered by AMP design, in terms of peptide sequence and post-synthetic chemical modification, we expect that many novel peptides of relevance in the fight against microbial infection and resistance will be identified and that the number of AMPs tested in the clinic will soon increase.

Author contributions

Costanza Montis: writing – original draft, review & editing and conceptualization; Elisa Marelli: writing – original draft, review & editing; Francesco Valle: writing – original draft, review & editing; Francesca Baldelli Bombelli: funding acquisition and writing – original draft, review & editing; Claudia Pigliacelli: writing – original draft, review & editing and conceptualization.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

FBB acknowledges the project Lancelot (PRIN 2022 PNRR n P2022RBF5P) funded by MUR (European Union – Next Generation EU).

References

- 1 C. J. Murray, K. S. Ikuta, F. Sharara, L. Swetschinski, G. Robles Aguilar, A. Gray, C. Han, C. Bisignano, P. Rao, E. Wool, S. C. Johnson, A. J. Browne, M. G. Chipeta, F. Fell, S. Hackett, G. Haines-Woodhouse, B. H. Kashef Hamadani, E. A. P. Kumaran, B. McManigal, R. Agarwal, S. Akech, S. Albertson, J. Amuasi, J. Andrews, A. Aravkin, E. Ashley, F. Bailey, S. Baker, B. Basnyat, A. Bekker, R. Bender, A. Bethou, J. Bielicki, S. Boonkasidecha, J. Bukosia, C. Carvalheiro, C. Castañeda-Orjuela, V. Chansamouth, S. Chaurasia, S. Chiurchiù, F. Chowdhury, A. J. Cook, B. Cooper, T. R. Cressey, E. Criollo-Mora, M. Cunningham, S. Darboe, N. P. J. Day, M. De Luca, K. Dokova, A. Dramowski, S. J. Dunachie, T. Eckmanns, D. Eibach, A. Emami, N. Feasey, N. Fisher-Pearson, K. Forrest, D. Garrett, P. Gastmeier, A. Z. Giref, R. C. Greer, V. Gupta, S. Haller, A. Haselbeck, S. I. Hay, M. Holm, S. Hopkins, K. C. Iregbu, J. Jacobs, D. Jarovsky, F. Javanmardi, M. Khorana, N. Kissoon, E. Kobeissi, T. Kostyaney, F. Krapp, R. Krumkamp, A. Kumar, H. H. Kyu, C. Lim, D. Limmathurotsakul, M. J. Loftus, M. Lunn, J. Ma, N. Mturi, T. Munera-Huertas, P. Musicha, M. M. Mussi-Pinhata, T. Nakamura, R. Nanavati, S. Nangia, P. Newton, C. Ngoun, A. Novotney, D. Nwakanma, C. W. Obiero, A. Olivas-Martinez, P. Olliaro, E. Ooko, E. Ortiz-Brizuela, A. Y. Peleg, C. Perrone, N. Plakkal, A. Ponce-de-Leon, M. Raad, T. Ramdin, A. Riddell, T. Roberts, J. V. Robotham, A. Roca, K. E. Rudd, N. Russell, J. Schnall, J. A. G. Scott, M. Shivamallappa, J. Sifuentes-Osornio, N. Steenkeste, A. J. Stewardson, T. Stoeva, N. Tasak, A. Thaiprakong, G. Thwaites, C. Turner, P. Turner, H. R. van Doorn, S. Velaphi, A. Vongpradith, H. Vu, T. Walsh, S. Waner, T. Wangrangsamakul, T. Wozniak, P. Zheng, B. Sartorius, A. D. Lopez, A. Stergachis, C. Moore, C. Dolecek and M. Naghavi, *Lancet*, 2022, **399**, 629–655.
- 2 M. McKenna, *Nature*, 2020, **584**, 338–341.
- 3 J. A. Doolan, G. T. Williams, K. L. F. Hilton, R. Chaudhari, J. S. Fossey, B. T. Goult and J. R. Hiscock, *Chem. Soc. Rev.*, 2022, **51**, 8696–8755.
- 4 U. Theuretzbacher, K. Outtersson, A. Engel and A. Karlén, *Nat. Rev. Microbiol.*, 2020, **18**, 275–285.
- 5 M. A. Cook and G. D. Wright, *Sci. Transl. Med.*, 2022, **14**, eabo7793.
- 6 G. Sun, Q. Zhang, Z. Dong, D. Dong, H. Fang, C. Wang, Y. Dong, J. Wu, X. Tan, P. Zhu and Y. Wan, *Front. Public Health*, 2022, **10**, 1002015.
- 7 L. Lombardi, A. Falanga, V. Del Genio and S. Galdiero, *Pharmaceutics*, 2019, **11**, 166.
- 8 L. Wang, N. Wang, W. Zhang, X. Cheng, Z. Yan, G. Shao, X. Wang, R. Wang and C. Fu, *Signal Transduction Targeted Ther.*, 2022, **7**, 48.
- 9 A. H. Benfield and S. T. Henriques, *Front. Med. Technol.*, 2020, **2**, 25–28.
- 10 N. G. J. Oliveira, M. H. Cardoso, N. Velikova, M. Giesbers, J. M. Wells, T. M. B. Rezende, R. de Vries and O. L. Franco, *Sci. Rep.*, 2020, **10**, 1–11.
- 11 F. Savini, M. R. Loffredo, C. Troiano, S. Bobone, N. Malanovic, T. O. Eichmann, L. Caprio, V. C. Canale, Y. Park, M. L. Mangoni and L. Stella, *Biochim. Biophys. Acta, Biomembr.*, 2020, **1862**, 183291.
- 12 M. H. Cardoso, B. T. Meneguetti, B. O. Costa, D. F. Buccini, K. G. N. Oshiro, S. L. E. Preza, C. M. E. Carvalho, L. Migliolo and O. L. Franco, *Int. J. Mol. Sci.*, 2019, **20**, 4877.
- 13 D. J. Trojanowska, G. Suarato, C. Braccia, A. Armirotti, F. Fiorentini, A. Athanassiou and G. Perotto, *ACS Appl. Nano Mater.*, 2022, **5**, 15272–15287.
- 14 H. Gong, J. Zhang, X. Hu, Z. Li, K. Fa, H. Liu, T. A. Waigh, A. McBain and J. R. Lu, *ACS Appl. Mater. Interfaces*, 2019, **11**, 34609–34620.



- 15 A. Hollmann, M. Martínez, M. E. Noguera, M. T. Augusto, A. Disalvo, N. C. Santos, L. Semorile and P. C. Maffia, *Colloids Surf., B*, 2016, **141**, 528–536.
- 16 S. Kim, J. Lee, S. Lee, H. Kim, J.-Y. Sim, B. Pak, K. Kim and J. Il Kim, *Commun. Biol.*, 2022, **5**, 1199.
- 17 F. H. Waghui and S. Idicula-Thomas, *Protein Sci.*, 2020, **29**, 36–42.
- 18 C. Wang, T. Hong, P. Cui, J. Wang and J. Xia, *Adv. Drug Delivery Rev.*, 2021, **175**, 113818.
- 19 S. He, Z. Yang, X. Li, H. Wu, L. Zhang, A. Shan and J. Wang, *Acta Biomater.*, 2023, **164**, 175–194.
- 20 T. Ganz, *Nat. Rev. Immunol.*, 2003, **3**, 710–720.
- 21 S. Guha, J. Ghimire, E. Wu and W. C. Wimley, *Chem. Rev.*, 2019, **119**, 6040–6085.
- 22 P. Askari, M. H. Namaei, K. Ghazvini and M. Hosseini, *BMC Pharmacol. Toxicol.*, 2021, **22**, 1–12.
- 23 J. S. Depelteau, S. Brenzinger and A. Briegel, Bacterial and Archeal Cell Structure, in *Encyclopedia of Microbiology*, ed. T. M. B. T.-E. of M. and E. Schmidt, Academic Press, Oxford, 4th edn, 2019, pp. 348–360.
- 24 L. Pasquina-Lemonche, J. Burns, R. D. Turner, S. Kumar, R. Tank, N. Mullin, J. S. Wilson, B. Chakrabarti, P. A. Bullough, S. J. Foster and J. K. Hobbs, *Nature*, 2020, **582**, 294–297.
- 25 T. J. Silhavy, D. Kahne and S. Walker, *Cold Spring Harbor Perspect. Biol.*, 2010, **2**, 1–16.
- 26 E. R. Rojas, G. Billings, P. D. Odermatt, G. K. Auer, L. Zhu, A. Miguel, F. Chang, D. B. Weibel, J. A. Theriot and K. C. Huang, *Nature*, 2018, **559**, 617–621.
- 27 K. L. May and M. Grabowicz, *Proc. Natl. Acad. Sci. U. S. A.*, 2018, **115**, 8852–8854.
- 28 D. Poger, S. Pöyry and A. E. Mark, *ACS Omega*, 2018, **3**, 16453–16464.
- 29 A. Ebbensgaard, H. Mordhorst, F. M. Aarestrup and E. B. Hansen, *Front. microbiol.*, 2018, **9**, 1–13.
- 30 J. Li, J. J. Koh, S. Liu, R. Lakshminarayanan, C. S. Verma and R. W. Beuerman, *Front. Neurosci.*, 2017, **11**, 1–18.
- 31 D. I. Chan, E. J. Prenner and H. J. Vogel, *Biochim. Biophys. Acta, Biomembr.*, 2006, **1758**, 1184–1202.
- 32 Z. Yang, H. Choi and J. C. Weisshaar, *Biophys. J.*, 2018, **114**, 368–379.
- 33 D. J. Slotboom, T. W. Ettema, M. Nijland and C. Thangaratnarajah, *FEBS Lett.*, 2020, **594**, 3898–3907.
- 34 D. Ghilarov, S. Inaba-Inoue, P. Stepien, F. Qu, E. Michalczyk, Z. Pakosz, N. Nomura, S. Ogasawara, G. C. Walker, S. Rebuffat, S. Iwata, J. G. Heddle and K. Beis, *Sci. Adv.*, 2021, **7**, eabj5363.
- 35 J. Frimodt-Møller, C. Campion, P. E. Nielsen and A. Løbner-Olesen, *Curr. Genet.*, 2022, **68**, 83–90.
- 36 J. S. M. Svendsen, T. M. Grant, D. Rennison, M. A. Brimble and J. Svenson, *Acc. Chem. Res.*, 2019, **52**, 749–759.
- 37 G. Wang, *Curr. Biotechnol.*, 2012, **1**, 72–79.
- 38 J. Andrä, D. Monreal, G. M. De Tejada, C. Olak, G. Brezesinski, S. S. Gomez, T. Goldmann, R. Bartels, K. Brandenburg and I. Moriyon, *J. Biol. Chem.*, 2007, **282**, 14719–14728.
- 39 Z. Jiang, A. I. Vasil, J. D. Hale, R. E. W. Hancock, M. L. Vasil and R. S. Hodges, *Biopolym. - Pept. Sci. Sect.*, 2008, **90**, 369–383.
- 40 I. Greco, N. Molchanova, E. Holmedal, H. Jenssen, B. D. Hummel, J. L. Watts, J. Håkansson, P. R. Hansen and J. Svenson, *Sci. Rep.*, 2020, **10**, 1–13.
- 41 J. J. López Cascales, S. Zenak, J. García De La Torre, O. G. Lezama, A. Garro and R. D. Enriz, *ACS Omega*, 2018, **3**, 5390–5398.
- 42 Y. Wu, Q. He, X. Che, F. Liu, J. Lu and X. Kong, *Biochem. Biophys. Res. Commun.*, 2023, **648**, 66–71.
- 43 S. Clark, T. A. Jowitt, L. K. Harris, C. G. Knight and C. B. Dobson, *Commun. Biol.*, 2021, **4**, 605.
- 44 Y. Yang and C. L. Dias, *J. Phys. Chem. B*, 2023, **127**, 912–920.
- 45 B. Mattei, A. Miranda, K. R. Perez and K. A. Riske, *Langmuir*, 2014, **30**, 3513–3521.
- 46 K. Wang, J. D. Keasling and S. J. Muller, *Int. J. Biol. Macromol.*, 2005, **36**, 232–240.
- 47 I. A. Edwards, A. G. Elliott, A. M. Kavanagh, J. Zuegg, M. A. T. Blaskovich and M. A. Cooper, *ACS Infect. Dis.*, 2016, **2**, 442–450.
- 48 B. H. Gan, J. Gaynord, S. M. Rowe, T. Deingruber and D. R. Spring, *Chem. Soc. Rev.*, 2021, **50**, 7820–7880.
- 49 Z. Yang, Y. Wei, W. Wu, L. Zhang, J. Wang and A. Shan, *Food Funct.*, 2023, **14**, 3139–3154.
- 50 M. Fernández-Vidal, S. Jayasinghe, A. S. Ladokhin and S. H. White, *J. Mol. Biol.*, 2007, **370**, 459–470.
- 51 T. Wang, C. Zou, N. Wen, X. Liu, Z. Meng, S. Feng, Z. Zheng, Q. Meng and C. Wang, *J. Pept. Sci.*, 2021, **27**, e3306.
- 52 I. Zelezetsky and A. Tossi, *Biochim. Biophys. Acta, Biomembr.*, 2006, **1758**, 1436–1449.
- 53 S. Lohan, A. G. Konshina, R. G. Efremov, I. Maslennikov and K. Parang, *J. Med. Chem.*, 2023, **66**, 855–874.
- 54 S. Fernandez-Lopez, H. Kim, E. C. Choi, M. Delgado, J. R. Granja, A. Khasanov, K. Kraehenbuehl, G. Long, D. A. Weinberger, K. M. Wilcoxon and M. R. Ghadiri, *Nature*, 2001, **412**, 452–455.
- 55 R. Shukla, F. Lavore, S. Maity, M. G. N. Derks, C. R. Jones, B. J. A. Vermeulen, A. Melcrová, M. A. Morris, L. M. Becker, X. Wang, R. Kumar, J. Medeiros-Silva, R. A. M. van Beekveld, A. M. J. J. Bonvin, J. H. Lorent, M. Lelli, J. S. Nowick, H. D. MacGillavry, A. J. Peoples, A. L. Spoering, L. L. Ling, D. E. Hughes, W. H. Roos, E. Breukink, K. Lewis and M. Weingarh, *Nature*, 2022, **608**, 390–396.
- 56 D. Glatzová, H. Mavila, M. C. Saija, T. Chum, L. Cwiklik, T. Brdička and M. Cebecauer, *FEBS J.*, 2021, **288**, 4039–4052.
- 57 R. P. Bywater, D. Thomas and G. Vriend, *J. Comput.-Aided Mol. Des.*, 2001, **15**, 533–552.
- 58 A. Gori, G. Lodigiani, S. G. Colombaroli, G. Bergamaschi and A. Vitali, *ChemMedChem*, 2023, **18**, e202300236.
- 59 A. Y. Gahane, P. Ranjan, V. Singh, R. K. Sharma, N. Sinha, M. Sharma, R. Chaudhry and A. K. Thakur, *Soft Matter*, 2018, **14**, 2234–2244.
- 60 E. González-Freire, F. Novelli, A. Pérez-Estévez, R. Seoane, M. Amorín and J. R. Granja, *Chem. – Eur. J.*, 2021, **27**, 3029–3038.
- 61 A. Rice and J. Wereszczynski, *Biochim. Biophys. Acta, Biomembr.*, 2017, **1859**, 1941–1950.



- 62 A. Arora, S. Majhi and A. Mishra, *Mater. Today: Proc.*, 2022, **49**, 2392–2396.
- 63 A. K. Mishra, J. Choi, E. Moon and K. H. Baek, *Molecules*, 2018, **23**, 1–23.
- 64 A. Walrant, A. Bauzá, C. Girardet, I. D. Alves, S. Lecomte, F. Illien, S. Cardon, N. Chaianantakul, M. Pallerla, F. Burlina, A. Frontera and S. Sagan, *Biochim. Biophys. Acta, Biomembr.*, 2020, **1862**, 183098.
- 65 S. K. Straus, *Biochim. Biophys. Acta, Biomembr.*, 2024, **1866**, 184260.
- 66 W. Li, F. Separovic, N. M. O'Brien-Simpson and J. D. Wade, *Chem. Soc. Rev.*, 2021, 50.
- 67 E. Grimsey, D. W. P. Collis, R. Mikut and K. Hilpert, *Biochim. Biophys. Acta, Biomembr.*, 2020, **1862**, 183195.
- 68 A. Makovitzki, D. Avrahami and Y. Shai, *Proc. Natl. Acad. Sci. U. S. A.*, 2006, **103**, 15997–16002.
- 69 J. L. Narayana, R. Golla, B. Mishra, X. Wang, T. Lushnikova, Y. Zhang, A. Verma, V. Kumar, J. Xie and G. Wang, *ACS Infect. Dis.*, 2021, **7**, 1795–1808.
- 70 Y. Wang, M. Xue, R. Gao, S. Chakraborty, S. Wang, X. Zhao, M. Gu, C. Cao, X. Sun and J. Cai, *Int. J. Mol. Sci.*, 2023, **24**, 6407.
- 71 C. Zhong, N. Zhu, Y. Zhu, T. Liu, S. Gou, J. Xie, J. Yao and J. Ni, *Eur. J. Pharm. Sci.*, 2020, **141**, 105123.
- 72 Y. Zai, Y. Ying, Z. Ye, M. Zhou, C. Ma, Z. Shi, X. Chen, X. Xi, T. Chen and L. Wang, *Antibiotics*, 2020, **9**, 1–19.
- 73 A. J. Craig, Y. Ermolovich, A. Cameron, A. Rodler, H. Wang, J. A. Hawkes, M. Hubert, F. Björkling, N. Molchanova, M. A. Brimble, L. W. K. Moodie and J. Svenson, *ACS Med. Chem. Lett.*, 2023, **14**, 802–809.
- 74 N. Molchanova, J. E. Nielsen, K. B. Sørensen, B. K. Prabhala, P. R. Hansen, R. Lund, A. E. Barron and H. Jenssen, *Sci. Rep.*, 2020, **10**, 1–10.
- 75 F. Jia, Y. Zhang, J. Wang, J. Peng, P. Zhao, L. Zhang, H. Yao, J. Ni and K. Wang, *Peptides*, 2019, **112**, 56–66.
- 76 X. Guo, X. Miao, Y. An, T. Yan, Y. Jia, B. Deng, J. Cai, W. Yang, W. Sun, R. Wang and J. Xie, *Eur. J. Med. Chem.*, 2024, **264**, 116001.
- 77 M. Mardirossian, M. Rubini, M. F. A. Adamo, M. Scocchi, M. Saviano, A. Tossi, R. Gennaro and A. Caporale, *Molecules*, 2021, **26**, 7401.
- 78 D. Neubauer, M. Jaśkiewicz, E. Sikorska, S. Bartoszewska, M. Bauer, M. Kapusta, M. Narajczyk and W. Kamysz, *Int. J. Mol. Sci.*, 2020, **21**, 1–30.
- 79 A. Pizzi, C. Pigliacelli, G. Bergamaschi, A. Gori and P. Metrangolo, *Coord. Chem. Rev.*, 2020, **411**, 213242.
- 80 A. Marchetti, A. Pizzi, G. Bergamaschi, N. Demitri, U. Stollberg, U. Diederichsen, C. Pigliacelli and P. Metrangolo, *Chem. – Eur. J.*, 2022, **28**, e202104089.
- 81 D. Maiolo, A. Pizzi, A. Gori, G. Bergamaschi, C. Pigliacelli, L. Gazzera, A. Consonni, F. Baggi, F. Moda, F. Baldelli Bombelli, P. Metrangolo and G. Resnati, *Supramol. Chem.*, 2020, **32**, 247–255.
- 82 A. Pizzi, L. Sori, C. Pigliacelli, A. Gautieri, C. Andolina, G. Bergamaschi, A. Gori, P. Panine, A. M. Grande, M. B. Linder, F. Baldelli Bombelli, M. Soncini and P. Metrangolo, *Small*, 2022, **18**, 2200807.
- 83 A. Levin, T. A. Hakala, L. Schnaider, G. J. L. Bernardes, E. Gazit and T. P. J. Knowles, *Nat. Rev. Chem.*, 2020, **4**, 615–634.
- 84 L. Lombardi, Y. Shi, A. Falanga, E. Galdiero, E. de Alteriis, G. Franci, I. Chourpa, H. S. Azevedo and S. Galdiero, *Biomacromolecules*, 2019, **20**, 1362–1374.
- 85 S. Malekhaat Häffner and M. Malmsten, *Curr. Opin. Colloid Interface Sci.*, 2018, **38**, 56–79.
- 86 Z. Ye and C. Aparicio, *Nanoscale Adv.*, 2019, **1**, 4679–4682.
- 87 F. Cao, G. Ma, M. Song, G. Zhu, L. Mei and Q. Qin, *Soft Matter*, 2021, **17**, 4445–4451.
- 88 A. P. McCloskey, B. F. Gilmore and G. Lavery, *Pathogens*, 2014, **3**, 792–821.
- 89 M. R. Ghadiri, J. R. Granja and L. K. Buehler, *Nature*, 1994, **369**, 301–304.
- 90 L. Motiei, S. Rahimpour, D. A. Thayer, C. H. Wong and M. R. Ghadiri, *Chem. Commun.*, 2009, 3693–3695.
- 91 D. J. Schibli, R. F. Epand, H. J. Vogel and R. M. Epand, *Biochem. Cell Biol.*, 2002, **80**, 667–677.
- 92 S. E. Blondelle and R. A. Houghten, *Trends Biotechnol.*, 1996, **14**, 60–65.
- 93 Q. Song, Z. Cheng, M. Kariuki, S. C. L. Hall, S. K. Hill, J. Y. Rho and S. Perrier, *Chem. Rev.*, 2021, **121**, 13936–13995.
- 94 E. H. M. Mohammed, S. Lohan, T. Ghaffari, S. Gupta, R. K. Tiwari and K. Parang, *J. Med. Chem.*, 2022, **65**, 15819–15839.
- 95 E. H. M. Mohammed, S. Lohan, R. K. Tiwari and K. Parang, *Eur. J. Med. Chem.*, 2022, **235**, 114278.
- 96 D. Oh, J. Sun, A. Nasrolahi Shirazi, K. L. LaPlante, D. C. Rowley and K. Parang, *Mol. Pharmaceutics*, 2014, **11**, 3528–3536.
- 97 M. P. Hendricks, K. Sato, L. C. Palmer and S. I. Stupp, *Acc. Chem. Res.*, 2017, **50**, 2440–2448.
- 98 K. Fa, H. Liu, H. Gong, L. Zhang, M. Liao, X. Hu, D. Ciumac, P. Li, J. Webster, J. Petkov, R. K. Thomas and J. R. Lu, *Langmuir*, 2022, **38**, 6623–6637.
- 99 R. Kowalczyk, P. W. R. Harris, G. M. Williams, S.-H. Yang and M. A. Brimble, Peptide Lipidation - a Synthetic Strategy to Afford Peptide Based Therapeutics, in *Peptides and Peptide-Based Biomaterials and Their Biomedical Applications*, ed. A. Sunna and P. L. Bergquist, Springer International Publishing, Cham, 2017, pp. 185–227.
- 100 J. D. Hartgerink, E. Beniash and S. I. Stupp, *Science*, 2001, **294**, 1684–1688.
- 101 A. Dehsorkhi, V. Castelletto and I. W. Hamley, *J. Pept. Sci.*, 2014, **20**, 453–467.
- 102 E. Kamysz, E. Sikorska, M. Jaśkiewicz, M. Bauer, D. Neubauer, S. Bartoszewska, W. Barańska-Rybak and W. Kamysz, *Int. J. Mol. Sci.*, 2020, **21**, 887.
- 103 D. A. Heesterbeek, B. W. Bardoel, E. S. Parsons, I. Bennett, M. Ruyken, D. J. Doorduijn, R. D. Gorham, E. T. Berends, A. L. Pyne, B. W. Hoogenboom and S. H. Rooijakkers, *EMBO J.*, 2019, **38**, e99852.
- 104 A. Adak, V. Castelletto, A. de Sousa, K.-A. Karatzas, C. Wilkinson, N. Khunti, J. Seitsonen and I. W. Hamley, *Biomacromolecules*, 2024, **25**, 1205–1213.



- 105 Z. Lai, H. Chen, X. Yuan, J. Tian, N. Dong, X. Feng and A. Shan, *Front. microbiol.*, 2022, **13**, 1–14.
- 106 C. J. C. Edwards-Gayle, V. Castelletto, I. W. Hamley, G. Barrett, F. Greco, D. Hermida-Merino, R. P. Rambo, J. Seitsonen and J. Ruokolainen, *ACS Appl. Bio Mater.*, 2019, **2**, 2208–2218.
- 107 S. Chou, H. Guo, F. G. Zingl, S. Zhang, J. Toska, B. Xu, Y. Chen, P. Chen, M. K. Waldor, W. Zhao, J. J. Mekalanos and X. Mou, *Proc. Natl. Acad. Sci. U. S. A.*, 2023, **120**, e2219679120.
- 108 Y. Wan, Y. Yang, M. Wu and S. Feng, *Expert Opin. Drug Delivery*, 2022, **19**, 1435–1448.
- 109 Z. Zhang, W. Shen, J. Ling, Y. Yan, J. Hu and Y. Cheng, *Nat. Commun.*, 2018, **9**, 1377.
- 110 G. Rong, C. Wang, L. Chen, Y. Yan and Y. Cheng, *Sci. Adv.*, 2020, **6**, eaaz1774.
- 111 S. Vauthey, S. Santoso, H. Gong, N. Watson and S. Zhang, *Proc. Natl. Acad. Sci. U. S. A.*, 2002, **99**, 5355–5360.
- 112 L. K. Vestby, T. Grønseth, R. Simm and L. L. Nesse, *Antibiotics*, 2020, **9**, 59.
- 113 V. Castelletto, R. H. Barnes, K.-A. Karatzas, C. J. C. Edwards-Gayle, F. Greco, I. W. Hamley, R. Rambo, J. Seitsonen and J. Ruokolainen, *Biomacromolecules*, 2018, **19**, 2782–2794.
- 114 A. Dehsorkhi, V. Castelletto, I. W. Hamley, J. Seitsonen and J. Ruokolainen, *Langmuir*, 2013, **29**, 14246–14253.
- 115 I. W. Hamley, A. Dehsorkhi and V. Castelletto, *Chem. Commun.*, 2013, **49**, 1850.
- 116 S. Debnath, A. Shome, D. Das and P. K. Das, *J. Phys. Chem. B*, 2010, **114**, 4407–4415.
- 117 N. Chauhan and Y. Singh, *ACS Biomater. Sci. Eng.*, 2020, **6**, 5507–5518.
- 118 M. A. Sani and F. Separovic, *Acc. Chem. Res.*, 2016, **49**, 1130–1138.
- 119 D. Ciumac, H. Gong, X. Hu and J. R. Lu, *J. Colloid Interface Sci.*, 2019, **537**, 163–185.
- 120 K. L. Chen and G. D. Bothun, *Environ. Sci. Technol.*, 2014, **48**, 873–880.
- 121 C. Montis, P. Joseph, C. Magnani, A. Marín-Menéndez, F. Barbero, A. R. Estrada, R. Nepravishta, J. Angulo, A. Checcucci, A. Mengoni, C. J. Morris and D. Berti, *Colloids Surf., B*, 2020, **195**, 111266.
- 122 H. Ilyas, M. J. A. Van Der Plas, M. Agnoletti, S. Kumar, A. K. Mandal, H. S. Atreya, A. Bhunia and M. Malmsten, *Bioconjugate Chem.*, 2021, **32**, 1729–1741.
- 123 S. E. Ayscough, L. A. Clifton, M. W. A. Skoda and S. Titmuss, *J. Colloid Interface Sci.*, 2023, **633**, 1002–1011.
- 124 J. E. Nielsen, V. R. Koynarev and R. Lund, *Curr. Opin. Colloid Interface Sci.*, 2023, **66**, 101709.
- 125 H. Gong, X. Hu, M. Liao, K. Fa, D. Ciumac, L. A. Clifton, M. A. Sani, S. M. King, A. Maestro, F. Separovic, T. A. Waigh, H. Xu, A. J. McBain and J. R. Lu, *ACS Appl. Mater. Interfaces*, 2021, **13**, 16062–16074.
- 126 H. Gong, X. Hu, L. Zhang, K. Fa, M. Liao, H. Liu, G. Fragneto, M. Campana and J. R. Lu, *J. Colloid Interface Sci.*, 2023, **637**, 182–192.
- 127 H. Gong, M. A. Sani, X. Hu, K. Fa, J. W. Hart, M. Liao, P. Hollowell, J. Carter, L. A. Clifton, M. Campana, P. Li, S. M. King, J. R. P. Webster, A. Maestro, S. Zhu, F. Separovic, T. A. Waigh, H. Xu, A. J. McBain and J. R. Lu, *ACS Appl. Mater. Interfaces*, 2020, **12**, 55675–55687.
- 128 S. Anselmo, G. Sancataldo, H. Mørck Nielsen, V. Foderà and V. Vetri, *Langmuir*, 2021, **37**, 13148–13159.
- 129 B. P. Dyett, H. Yu, B. Lakic, N. De Silva, A. Dahdah, L. Bao, E. W. Blanch, C. J. Drummond and C. E. Conn, *J. Colloid Interface Sci.*, 2021, **600**, 14–22.
- 130 M. Hasan, F. Hossain, H. Dohra and M. Yamazaki, *Biochem. Biophys. Res. Commun.*, 2022, **630**, 50–56.
- 131 J. E. Nielsen, V. A. Bjørnstad, V. Pipich, H. Jenssen and R. Lund, *J. Colloid Interface Sci.*, 2021, **582**, 793–802.
- 132 N. Nuti, P. Rottmann, A. Stucki, P. Koch, S. Panke and P. S. Dittrich, *Angew. Chem., Int. Ed.*, 2022, **61**, e202114632.
- 133 S. M. Häffner, E. Parra-Ortiz, K. L. Browning, E. Jørgensen, M. W. A. Skoda, C. Montis, X. Li, D. Berti, D. Zhao and M. Malmsten, *ACS Nano*, 2021, **15**, 6787–6800.
- 134 R. Brasseur, M. Deleu, M. P. Mingeot-Leclercq, G. Francius and Y. F. Dufrène, *Surf. Interface Anal.*, 2008, **40**, 151–156.
- 135 M. Radmacher, *Methods Cell Biol.*, 2007, **83**, 347–372.
- 136 Y. F. Dufrène, T. Ando, R. Garcia, D. Alsteens, D. Martinez-Martin, A. Engel, C. Gerber and D. J. Müller, *Nat. Nanotechnol.*, 2017, **12**, 295–307.
- 137 F. Valle, J. A. DeRose, G. Dietler, M. Kawe, A. Plückthun and G. Semenza, *Ultramicroscopy*, 2002, **93**, 83–89.
- 138 A. Ridolfi, M. Brucale, C. Montis, L. Caselli, L. Paolini, A. Borup, A. T. Boysen, F. Loria, M. J. C. Van Herwijnen, M. Kleinjan, P. Nejsun, N. Zarovni, M. H. M. Wauben, D. Berti, P. Bergese and F. Valle, *Anal. Chem.*, 2020, **92**, 10274–10282.
- 139 F. Perissinotto, V. Rondelli, B. Senigagliaesi, P. Brocca, L. Almásy, L. Bottyán, D. G. Merkel, H. Amenitsch, B. Sartori, K. Pachler, M. Mayr, M. Gimona, E. Rohde, L. Casalis and P. Parisse, *Nanoscale*, 2021, **13**, 5224–5233.
- 140 F. Abbasi, J. Alvarez-Malmagro, Z. Su, J. J. Leitch and J. Lipkowski, *Langmuir*, 2018, **34**, 13754–13765.
- 141 J. M. Henderson, A. J. Waring, F. Separovic and K. Y. C. Lee, *Biophys. J.*, 2016, **111**, 2176–2189.
- 142 V. K. Sharma and S. Qian, *Langmuir*, 2019, **35**, 4152–4160.
- 143 Z. Shen, Z. Guo, L. Zhou, Y. Wang, J. Zhang, J. Hu and Y. Zhang, *Biomater. Sci.*, 2020, **8**, 2031–2039.
- 144 V. Montana, W. Liu, U. Mohideen and V. Parpura, *Croat. Chem. Acta*, 2008, **81**, 31–40.
- 145 J. D. Unsay, K. Cosentino and A. J. García-Sáez, *J. Visualized Exp.*, 2015, e52867.
- 146 S. Manioglou, S. M. Modaresi, N. Ritzmann, J. Thoma, S. A. Overall, A. Harms, G. Upert, A. Luther, A. B. Barnes, D. Obrecht, D. J. Müller and S. Hiller, *Nat. Commun.*, 2022, **13**, 6195.
- 147 E. H. L. Chen, C. H. Wang, Y. T. Liao, F. Y. Chan, Y. Kanaoka, T. Uchihashi, K. Kato, L. Lai, Y. W. Chang, M. C. Ho and R. P. Y. Chen, *Nat. Commun.*, 2023, **14**, 1–12.



Mini review

- 148 T. O. Paiva, A. Viljoen and Y. F. Dufrêne, *Nat. Commun.*, 2022, **13**, 10–12.
- 149 G. Benn, A. L. B. Pyne, M. G. Ryadnov and B. W. Hoogenboom, *Analyst*, 2019, **144**, 6944–6952.
- 150 H. Rudilla, A. Merlos, E. Sans-Serramitjana, E. Fuste, J. M. Sierra, A. Zalacain, T. Vinuesa and M. Vinas, *AIMS Microbiol.*, 2018, **4**, 522–540.
- 151 H. Shahrou, R. Ferrer-Espada, I. Dandache, S. Bárcena-Varela, S. Sánchez-Gómez, A. Chokr and G. Martinez-de-Tejada, AMPs as Anti-biofilm Agents for Human Therapy and Prophylaxis, in *Antimicrobial Peptides*, ed. K. Matsuzaki, 2019, vol. 1117, pp. 257–279.
- 152 A. P. McCloskey, E. R. Draper, B. F. Gilmore and G. Lavery, *J. Pept. Sci.*, 2017, **23**, 131–140.
- 153 C. J. Harding, M. Bischoff, M. Bergkessel and C. M. Czekster, *Nat. Chem. Biol.*, 2023, **19**, 1158–1166.
- 154 S. Parhi, S. Pal, S. K. Das and P. Ghosh, *Biotechnol. Bioeng.*, 2021, **118**, 4590–4622.
- 155 A. K. Tripathi, J. Singh, R. Trivedi and P. Ranade, *J. Funct. Biomater.*, 2023, **14**, 539.
- 156 C. D. Fjell, J. A. Hiss, R. E. W. Hancock and G. Schneider, *Nat. Rev. Drug Discovery*, 2012, **11**, 37–51.
- 157 P. Gagat, A. Duda-Madej, M. Ostrówka, F. Pietluch, A. Seniuk, P. Mackiewicz and M. Burdukiewicz, *Int. J. Mol. Sci.*, 2023, **24**, 804.
- 158 S. J. Lam, E. H. H. Wong, N. M. O'Brien-Simpson, N. Pantarat, A. Blencowe, E. C. Reynolds and G. G. Qiao, *ACS Appl. Mater. Interfaces*, 2016, **8**, 33446–33456.

